89bio, Inc.
ETNB
$9.03
-$0.39-4.14%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.10% | 16.92% | 40.56% | 32.40% | 18.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.75% | 32.53% | 196.09% | 286.17% | 26.84% |
| Operating Income | -116.75% | -32.53% | -196.09% | -286.17% | -26.84% |
| Income Before Tax | -131.52% | -37.91% | -224.73% | -328.71% | -24.60% |
| Income Tax Expenses | 461.94% | 41.24% | -93.35% | -- | -- |
| Earnings from Continuing Operations | -132.44% | -37.91% | -194.16% | -329.30% | -24.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.44% | -37.91% | -194.16% | -329.30% | -24.95% |
| EBIT | -116.75% | -32.53% | -196.09% | -286.17% | -26.84% |
| EBITDA | -116.79% | -32.53% | -196.18% | -286.25% | -26.84% |
| EPS Basic | -46.99% | 9.68% | -104.71% | -206.05% | 7.22% |
| Normalized Basic EPS | -46.38% | 12.09% | -118.34% | -205.66% | 7.48% |
| EPS Diluted | -46.99% | 9.68% | -104.71% | -206.05% | 7.22% |
| Normalized Diluted EPS | -46.38% | 12.09% | -118.34% | -205.66% | 7.48% |
| Average Basic Shares Outstanding | 58.15% | 52.71% | 43.69% | 40.27% | 34.68% |
| Average Diluted Shares Outstanding | 58.15% | 52.71% | 43.69% | 40.27% | 34.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |